AI Article Synopsis
- The paper discusses the creation of new composite materials made from collagen (COLL) and hydroxyapatite (HA) that are loaded with the cancer drug cisplatin.
- The materials aim to mimic bone composition with specific weight ratios and deliver controlled concentrations of cisplatin (6 and 10 μM) in cell culture experiments.
- Results showed that these composites effectively kill cancer cells (specifically G292 osteosarcoma cells), suggesting they could be a promising method for treating bone cancer through targeted localized chemotherapy.
Article Abstract
In this paper, the synthesis and characterization of novel cisplatin-loaded collagen (COLL)/hydroxyapatite (HA) composite materials are presented. The composite materials were designed to obtain a COLL: HA weight ratio close to the bone composition. The content of embedded cisplatin was chosen to assure a concentration of cisplatin of 6 and 10 μM, respectively, into the culture media used in cell culture experiments. These cisplatin delivery systems were characterized by determining the physico-chemical properties of the composite material, the drug release process as well as their biological activity. Based on the in vitro data that showed the cytotoxic, anti-proliferative and anti-invasive activities of these multifunctional systems on G292 osteosarcoma cells in dependence on the cisplatin concentration released in culture medium, we conclude that the newly developed COLL/HA-cisplatin drug delivery system could be a feasible approach for locoregional chemotherapy of bone cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7785/tcrt.2012.500331 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!